Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PROKIDNEY CORP. (PROK)

ProKidney Q1 net loss widens to $42.6 million; cash falls to $224.9 million

Negative Impact 3 of 5 earnings Written later

ProKidney reported first-quarter 2026 results, with its net loss before noncontrolling interest widening to $42.6 million from $38.0 million a year earlier and revenue of $226 thousand against $230 thousand. The company also updated its Phase 3 PROACT 1 statistical powering assumption for the eGFR slope analysis to 80%, and said its cash supports operations into mid-2027, which matters to shareholders because the company's cash balance is declining while it funds the pivotal study.

Key points

  • Q1 2026 net loss before noncontrolling interest was $42.6 million, versus $38.0 million in Q1 2025; net loss per Class A share was $(0.14), versus $(0.13)
  • R&D expenses rose to $33.8 million from $27.3 million, driven mainly by PROACT 1 clinical study and manufacturing costs; G&A fell to $11.3 million from $14.4 million
  • Cash, cash equivalents and marketable securities totaled $224.9 million at March 31, 2026, down from $270.0 million at December 31, 2025; the company expects this to fund operations into mid-2027
  • PROACT 1 enrollment for the accelerated approval analysis is on track for mid-2026, with pivotal topline results expected in Q2 2027

The filing

CompanyPROKIDNEY CORP. (PROK)
Form8-K, current report
Filed with the SECMay 15, 2026, 11:49 AM ET
Accession number0001193125-26-225848

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.